Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for November 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in November 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1. Table of Contents

1. Table of Contents 2

1.1. List of Tables 5

1.2. List of Figures 7

2. Deal Values in Pharmaceutical and Healthcare Industry Has Increased in November 2019 9

2.1. Pharmaceuticals & Healthcare, Deals Summary, November 2019 9

3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13

3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, November 2019 13

3.2. Pharmaceuticals & Healthcare, Global, Major Deals, November 2019 14

3.2.1. AbbVie Raises USD30 Billion in Private Placement of Notes 15

3.2.2. Novartis to Acquire Medicines Co 15

3.2.3. Stryker to Acquire Wright Medical 16

3.2.4. Mitsubishi Chemical to Acquire Remaining

43.61% Stake in Mitsubishi Tanabe for USD4.52 Billion 16

3.2.5. Roche to Acquire Promedior for up to USD1.39 Billion 17

3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, November 2019 18

3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, November 2019 19

4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20

4.1. Pharmaceuticals & Healthcare, Global, M&A, November 2019 20

4.1.1. Top M&A Deals in November 2019 21

4.1.2. Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, June 2019 – November 2019 22

4.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals, November 2019 24

4.2.1. Top Equity Offering Deals in November 2019 25

4.2.2. Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, June 2019 – November 2019 26

4.3. Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, November 2019 28

4.3.1. Top PE/VC Deals in November 2019 29

4.3.2. Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, November 2019 30

4.3.3. Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, November 2019 32

4.3.5. Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2019–November 2019 34

4.3.7. Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2019–November 2019 35

4.4. Pharmaceuticals & Healthcare, Global, Partnership Deals, November 2019 36

4.5. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, June 2019 – November 2019 38

4.6. Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), November 2019 40

4.6.1. Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, November 2019 41

4.7. Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 42

4.8. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, June 2019 – November 2019 44

4.9. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), June 2019 – November 2019 45

4.10. Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 47

5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2019 49

5.1. Pharmaceuticals & Healthcare, Global, Licensing Agreements, November 2019 49

5.2. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), November 2019 51

5.3. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), June 2019 – November 2019 53

5.4. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), June 2019 – November 2019 55

5.5. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), June 2019 – November 2019 57

5.6. Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), June 2019 – November 2019 60

5.6.1. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, November 2019 61

5.6.2. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, November 2019 62

5.6.3. Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, November 2019 63

6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 64

6.1. Pharmaceuticals & Healthcare, Global, Oncology Deals, November 2019 64

6.1.1. Oncology – Deals of the Month 65

6.2. Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, November 2019 68

6.2.1. Central Nervous System – Deals of the Month 69

6.3. Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, November 2019 70

6.3.1. Infectious Diseases – Deals of the Month 71

6.4. Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, November 2019 72

6.4.1. Cardiovascular – Deals of the Month 73

6.5. Pharmaceuticals & Healthcare, Global, Immunology Deals, November 2019 74

6.5.1. Immunology – Deal of the Month 75

6.6. Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, November 2019 77

6.6.1. Metabolic – Deals of the Month 78

6.7. Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, November 2019 80

6.7.1. Gastrointestinal – Deals of the Month 81

7. Deal Summary by Geography 83

7.1. Pharmaceuticals & Healthcare, North America Deals, November 2019 83

7.1.1. North America – Deals of the Month 84

7.2. Pharmaceuticals & Healthcare, Europe, Deals, November 2019 86

7.2.1. Europe – Deals of the Month 87

7.3. Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, November 2019 89

7.3.1. Asia-Pacific – Deals of the Month 90

7.4. Pharmaceuticals & Healthcare, Rest of the World, Deals, November 2019 92

7.4.1. Rest of the World – Deals of the Month 93

8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 95

8.1. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, June 2019 – November 2019 95

8.2. Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, June 2019 – November 2019 97

9. Further Information 99

9.1. Methodology 99

9.2. About GlobalData 100

9.3. Contact Us 100

9.4. Disclosure information 100

9.5. Disclaimer 100

List of Tables

1.1. List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 14

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, November 2019 14

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), November 2019 19

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 21

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, November 2019 21

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2019 – November 2019 22

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 25

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, November 2019 25

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 27

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 29

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, November 2019 29

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, June 2019 – November 2019 30

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), November 2019 33

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 34

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2019 – November 2019 35

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 36

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 39

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 40

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), November 2019 41

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 43

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2019 – November 2019 45

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), June 2019 – November 2019 48

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 50

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 52

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 54

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), November 2019 56

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2019 – November 2019 59

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), November 2019 61

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, November 2019 61

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, November 2019 62

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, November 2019 63

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 65

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 69

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 71

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 73

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 75

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 78

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 81

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 84

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 87

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 90

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 93

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 96

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 98

List of Figures

1.2. List of Figures

Figure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, November 2019 9

Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, June 2019 – November 2019 10

Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, November 2019 11

Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, November 2019 12

Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 13

Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), November 2019 18

Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), November 2019 19

Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 20

Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2019 – November 2019 22

Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 24

Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 26

Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 28

Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, June 2019 – November 2019 30

Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), November 2019 32

Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), November 2019 33

Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 38

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 40

Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 42

Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2019 – November 2019 44

Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, June 2019 – November 2019 45

Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 47

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 49

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 51

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 53

Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), June 2019 – November 2019 55

Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, June 2019 – November 2019 57

Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), June 2019 – November 2019 58

Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), November 2019 60

Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 64

Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 68

Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 70

Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 72

Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 74

Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 77

Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 80

Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 83

Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 86

Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 89

Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 92

Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 95

Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), June 2019 – November 2019 97

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports